tbuckley/cabot-search huggingface dataset:
Abstract 17194: Incremental Value of JTc Interval in Improving Risk Stratification for Life-Threatening Ventricular Arrhythmias in Patients Considered Low Risk by LVEF
Authors: Mohsin Khan, Susan Olet, Mohammad E Mortada, Firas Zahwe, Jodi Zilinski, Vikram Nangia, Anwer Dhala, Indrajit Choudhuri, Atul Bhatia, Imran Niazi, Jasbir Sra, Arshad Jahangir
Journal: Circulation (2018)

Introduction: ICD implantation is recommended in patients with LVEF&lt;35%, while those with LVEF between 35 to 40% are not considered at high risk for primary prevention ICD implantation. A subset of these patients develops life threatening ventricular arrhythmias (VA) and improvement in risk stratification may help identify and implement life-saving intervention. Hypothesis: Prolonged repolarization is a marker of electrical instability and JTc interval on ECG could provide prognostic information in patients with LVEF 35-40% incremental to that from LVEF. Methods: Patients ≥18 yr with no history of VA and an ECG and echocardiogram obtained at initial encounter between 11/2011 to 12/2016 with long-term follow-up were identified. The incremental predictive ability of JTc interval on improvement in risk stratification for VA was determined by receiver operating characteristics (ROC) curve, integrated discrimination improvement (IDA) and net reclassification improvement (NRI) analysis. All tests were performed at a 5% level of significance. Results: Out of 29,700 pts that met inclusion criteria, 1,102 (3.7%) had LVEF 35-40% (mean age 70.5±14.6 yrs, 49% males, CAD 67%) and 24,894 (84%) LVEF &gt;40% (65.9±16.3 yrs , 61.8% M). Over the mean follow-up of 4.6±4.2 years, the incidence of VT/VF/cardiac arrest was 16.1% in patients with LVEF 35-40% compared to 4.1% with LVEF &gt;40%. For every 50 ms increase in JTc interval above 300 ms, the risk for arrhythmic event in LVEF 35-40% increased two-fold (Odds Ratio=1.83 (95 % CI 1.72-1.94, P=0.013). Incorporation of JTc to LVEF improved the C statistics (95% Confidence Limit) in the model with only LVEF from 0.56 (0.54-0.57) to 0.72 (0.70-0.73) for the model combining LVEF and JTc. In addition, NRI was estimated at 0.57, which was statistically significant with p values &lt;0.001 while IDI was estimated as 0.015 with p values &lt;0.001 for the model incorporating JTc to LVEF. Conclusions: In patients with LVEF 35-40% considered low risk for life threatening VA by EF, incorporating JTc interval information improved risk stratification and identified those who subsequently developed VT/VF or cardiac arrest and thus identifies a subgroup that can benefit from prophylactic ICD implantation.
Association of COVID‐19 with skin diseases and relevant biologics
Journal: British Journal of Dermatology (2021)

There is concern about the association between coronavirus disease 2019 (COVID-19) and skin diseases, or relevant 'biologics'a type of drug used to treat some skin diseases.This study analysed a nationwide dataset relevant to COVID-19 in South Korea.The dataset contained a total of 234 427 people who underwent COVID-19 testing (111 947 male and 122 480 female).Of them, 7590 (3Á2%) were confirmed as COVID-19 positive, and 227 (3Á0%) confirmed COVID-19 positive patients died.No significant increase in the presence of specific skin diseases or exposure to biologics was observed in the COVID-19 positive group.The presence of skin diseases and exposure to biologics also did not seem to affect clinical outcomes (the severity of COVID-19 infection) or mortality (likelihood of dying from COVID-19).This study showed that underlying skin diseases or exposure to relevant biologics did not appear to increase susceptibility to coronavirus disease, or mortality from coronavirus disease.Biologics for dermatological conditions might be continuously used during the COVID-19 pandemic.
BRAZIL
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Figure 3
Authors: Alan Davis, Roland Griffiths
Journal: JAMA Psychiatry (2021)

Jasmin Wertz, PhD; Avshalom Caspi, PhD; Antony Ambler, MSc; Jonathan Broadbent, PhD; Robert J. Hancox, MD; HonaLee Harrington, BA; Sean Hogan, MSW; Renate M. Houts, PhD; Joan H. Leung, PhD; Richie Poulton, PhD; Suzanne C. Purdy, PhD; Sandhya Ramrakha, PhD; Line Jee Hartmann Rasmussen, PhD; Leah S. Richmond-Rakerd, PhD; Peter R. Thorne, PhD; Graham A. Wilson, MBChB; Terrie E. Moffitt, PhD
BOOK REVIEWS
Authors: R. CHAMPLIN
Journal: JNCI Journal of the National Cancer Institute (1991)

BOOK REVIEWS Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment, Volume 2, Hematology . Steven J. Burakoff , H. Joachim Deeg , James Ferrara , Kerry Atkinson , eds. New York : Marcel Dekker , 1990 , 816 pp. $175. RICHARD CHAMPLIN RICHARD CHAMPLIN Department of Hematology, MD Anderson Cancer Center, Texas Medical Center1515 Holcombe Blvd, Houston, Tx 77030 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 8, 17 April 1991, Pages 576–577, https://doi.org/10.1093/jnci/83.8.576-a Published: 17 April 1991
Prospective, randomized, crossover evaluation of the effect of propranolol, nadolol, and placebo on neurocardiogenic syncope recurrence and patients' well-being Panagiota Flevari, Efthimios G. Livanis, George N. Theodorakis, Elizas Zarvalis, Dimitrios T. Kremastinos. Onassis Cardiac Surgery Center, Athens, Greece
Journal: Journal of the American College of Cardiology (2001)
Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America.
Authors: Chris Pescott, Adam Kasle, Federico Esteso, Stephen Stefani, Leandro Brust, Jose Pinto, Malena Tilli, Matthew Massello
Journal: Journal of Clinical Oncology (2022)

203 Background: Anti-EGFR treatment of RAS wild-type metastatic colorectal cancer (mCRC) in Latin America includes cetuximab or panitumumab, added to chemotherapy (cet+CT and pan+CT, respectively). Adverse event (AE) profiles for each regimen may influence the treatment decision. This study aimed to estimate the associated financial impact of AE management in three countries: Argentina (AR), Brazil (BR) and Panama (PA) from a healthcare payer perspective. Methods: We revised a published Microsoft Excel-based economic model to calculate average patient- and population-level costs from a payer perspective of mCRC AE management for first-line cet+CT and pan+CT treatment, using AE frequency and severity data derived from the authorization relevant FDA prescribing information (PI), multiplied by the country-specific unit costs of managing AEs. Costs of AE management were obtained from publicly available sources in each country and converted to US dollars (USD). Country-specific market research data were applied to calculate costs at the eligible mCRC population level. The model structure and input parameters were endorsed by local practising oncologists. Results: A 17.5% (all-grade) and 31.6% (grade 3-4) lower average per patient AE frequency were estimated from the PI, for cet+CT vs pan+CT. Cost results are presented in the table. Projected AE management costs of cet+CT for the eligible mCRC population are $297,643 (AR), $124,981 (BR) and $65,895 (PA), annually, reducing current annual estimated AE costs by $42,181 (AR), $8,548 (BR) and $4,691 (PA). Conclusions: According to the average estimated AE frequencies, patients treated with cet+CT are expected to experience fewer AEs than with pan+CT. According to our analyses, the lower frequency rates could result in lower overall and severe AEs’ management costs, resulting in 12.4% (AR), 6.4% (BR) and 6.6% (PA) lower costs of AE management for cet+CT versus pan+CT.[Table: see text]
Fetal Hemoglobin Variant of Unusual Genetic Interest
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Striking heterogeneity of responsiveness to glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and positive troponin Marco Roffi, L. Kristin Newby, Robert A. Harrington, Harvey D. White, Christian W. Hamm, Eric J. Topol. Cleveland Clinic Foundation, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition
Authors: Xin Chen, Ri-Xin Chen, Wen-Su Wei, Yong-Hong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gang-Jun Yuan, Si-Liang Chen, Sheng-Jie Guo, Kang-Hua Xiao, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, Dan Xie
Journal: Clinical Cancer Research (2021)

In the original version of [this article][1] ([1][2]), an incorrect image was used for the p-control cells in Fig. 2F. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret the error. 1. 1.[↵][3]1. Chen X, 2. Chen R-X, 3. Wei W-S
Central Pain Mechanisms
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Letter: Death after E.C.T.
Authors: J Baron
Journal: BMJ (1974)

|P.A.O.I Peak Acid Output (mEq/hr) x 100 Sex Age (Years) P.A.O.Histalog Insulin Hg F 34 18 5 0-88 5 M 66 1-24 0 0 M 63 17-58 9 54 54 results of gastric secretion tests8 are shown in the table.These results could be interoreted as showing absence of impairment of vagal innervation of the stomach in these three patients with peripheral and autonomic neuropathy.Kassander9 had originally sug- gested that "a diabetic patient at some point in the progression of his diabetes may 'vagotomize' himself."Myelin degeneration has been seen in the vagal nerves of diabetics as well as in their peripheral nerves.10Taken together these histological .abnormalities10 and the gastric secretory studies5 7 8 support this concept of the diabetic vagotomizing himse,lf,9 analogous to achalasia of the oesophagus.In 32 patients with achalasia vagal nerve function was considered absent in eight because of failure of acid response to insulin but adeauate response to maxi- mum Histalog stimulation.'1Autovagotomy should be considered as part of a spectrum of diabetic autonomic neuropathy, so that it is not surprising that the incidence of duodenal ulcer in diabetics is only one-third of that of the normal population.11-Iam, etc.,
Antecedent hypertension and risk of heart failure after myocardial infarction A. Mark Richards, M. Gary Nicholls, Richard W. Troughton, John G. Lainchbury, Christopher Frampton, Eric A. Espiner, Hamid Ikram, Tim G. Yandle, John Turner. Christchurch School of Medicine, Christchurch, New Zealand, Christchurch Hospital, Christchurch, New Zealand
Journal: Journal of the American College of Cardiology (2001)
Data bias
Authors: Teppo Felin, Jan Koenderink, Joachim I. Krueger, Denis Noble, George F. R. Ellis
Journal: Genome biology (2021)

Data is critical to science.But data itself is passive and inert.Data is not meaningful until it encounters an active, problem-solving observer.And in science, data gains relevance and becomes data in response to human questions, hypotheses, and theories.In their response, Yanai and Lercher (Y&L) mis-specify the role of data and hypotheses in science (Yanai I, Lercher M.: The data-hypothesis conversation, forthcoming).Their insistence on the hypothesis-free exploration of data in scientific discovery is problematic.On the surface, they are right: data matters.And, as they note, the scientific process can indeed be convoluted, as data and hypotheses are tightly linked.But Y&L's arguments suffer from a common bias where data is somehow seen as independent of hypothesis and theory.We respond to Y&L by revisiting their central points and examples.
Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.
Authors: Jagpreet Chhatwal, Sumeyye Samur, Ju Dong Yang, Lewis R. Roberts, Mindie Nguyen, A. Burak Ozbay, Turgay Ayer, Neehar Parikh, Amit G. Singal
Journal: Journal of Clinical Oncology (2022)

405 Background: Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer mortality in the United States. Although clinical guidelines recommend ultrasound (U/S), with or without the serum biomarker alpha fetoprotein (AFP) for HCC surveillance in at-risk patients, only 24% of patients adhere to surveillance and only one-third of HCCs are detected before developing symptoms. A multi-target HCC blood-based test (mt-HBT) was recently shown to have promising sensitivity for early HCC detection and may help improve surveillance adherence given its blood-based nature. Our objective was to evaluate the comparative clinical effectiveness of mt-HBT with the current standard-of-care surveillance strategy in patients with cirrhosis. Methods: We simulated a virtual trial by developing a microsimulation model of the natural history of HCC in patients with compensated (Child Pugh A) cirrhosis over a 30-year horizon. To inform model parameters, we used published data on tumor progression, competing risks of mortality, and real-world HCC surveillance adherence. Test performance characteristics were informed by a network meta-analysis. We simulated the life course of 51-year-old patients with cirrhosis and compared no surveillance with biannual surveillance using (1) AFP only, (2) U/S only, (3) U/S+AFP, (4) mt-HBT, and (5) mt-HBT with improved adherence. We assumed a blood-based test—without U/S—would improve surveillance adherence by 10% compared with current adherence (̃4% absolute improvement). Results: Per 100,000 cirrhosis patients, mt-HBT detected 6,220 more early-stage HCC than no surveillance, 2,250 (+57%) more than AFP, 1080 (+21%) more than U/S, and 200 (-3%) less than U/S+AFP. mt-HBT with improved adherence detected 210 (+3%) more early-stage HCC than U/S+AFP (Table). The remaining HCC cases were either symptomatic or the patients died per other competing causes prior to detection. The number of screening tests needed to detect one HCC were 296 for AFP, 287 for U/S, 253 for U/S+AFP, 254 for mt-HBT and 262 for mt-HBT with improved adherence. The number of diagnostic MRI/CT needed to detect one HCC were 40 for AFP, 38 for U/S, 45 for U/S+AFP, 37 for mt-HBT, and 38 for mt-HBT with improved adherence. Conclusions: mt-HBT detects more early-HCC cases than U/S and similar number of early-HCC cases with U/S+AFP. By decreasing surveillance barriers and increasing adherence, mt-HBT could improve early HCC detection and could be promising option for HCC surveillance in patients with cirrhosis. [Table: see text]
Restriction of HIV-1 Infection in Sickle Cell Disease and Trait
Authors: Namita Kumari, Miguel de Mulder, Javed Khan, Asrar Ahmad, Songping Wang, Hatajai Lassiter, Nathan Smith, Nowah Kokou Apeadoufia Afangbedji, Andrey Ivanov, Mitsu Shah, Sharmin Diaz, Sohail Rana, Douglas Nixon, Sergei Nekhai
Journal: Blood (2018)
Delayed left ventricular mass reduction with sustained antihypertensive treatment: The LIFE study Richard B. Devereux, Vittorio Palmieri, Jennifer E. Liu, Kristian Wachtell, Kurt Boman, Eva Gerdts, Markku S. Nieminen, Vasilios Papademetriou, Bjorn Dahlof. Weill Cornell Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
Real-time magnetic resonance image acquisition during dobutamine stress for the detection of left ventricular wall motion abnormalities in patients with coronary artery disease 3imon Schalla, Eike Nagel, Ingo Paetsch, Axel Bornstedt, Bernhard Schnackenburg, Hans Lehmkuhl, Christoph Klein, Eckart Fleck. German Heart Institute Berlin/Charite Campus Virchow, Berlin, Germany, Phillips Medical Systems, Hamburg, Germany
Journal: Journal of the American College of Cardiology (2001)
新冠疫苗接种后的各种皮肤反应
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Català et al. Br J Dermatol 2022; 186:142–152. 在临床试验中, 新冠疫苗接种可能产生相关皮肤反应。最常见的是所谓的“新冠臂”, 包括手臂注射部位发红、肿胀和疼痛。疫苗批准后和大规模接种期间, 报告了注射部位外的其他皮疹, 但描述不佳。 研究人员通过在线调查与西班牙的皮肤科医生合作, 收集了研究时获批的任何新冠疫苗 (Pfizer、Moderna 和 AstraZeneca) 在接种任何剂次后 21 天内发生的 405 起皮疹的信息。所有皮肤反应均经作者同意并借助图片进行描述和分类。 结果显示, 这些疫苗接种后发生的皮疹各异, 在女性中更常见。最明显的皮肤反应为“新冠臂”, 尤其发生在 Moderna 疫苗接种后, 是最常见的与一般症状相关的反应。此外, 还描述了其他更广泛的皮疹, 通常发痒, 包括风团 (荨麻疹) 、红色小肿块或水疱、红色鳞屑性斑片、麻疹样皮疹或紫色病变。此外, 还存在疱疹性感染 (主要是带状疱疹) 再激活, 尤其是在接种 Pfizer-BioNTech 疫苗后。AstraZeneca 疫苗接种后描述最多的皮肤反应是风团。这些皮疹大多为轻度, 需要使用抗组胺药和/或皮质类固醇治疗, 平均在 12 天内消退。 本研究可能有助于医疗保健工作者更好地识别这些皮疹, 并能够在新冠疫苗大规模接种期间为人群提供建议和安抚。 Linked Article: Català et al. Br J Dermatol 2022; 186:142–152.
Negative 68Ga–Prostate-Specific Membrane Antigen PET/CT Scan on a Recurrent Juvenile Nasopharyngeal Angiofibroma
Authors: Aswin Chandran, Hitesh Verma, Ashu Seith Bhalla, Rakesh Kumar, Aanchal Kakkar
Journal: Clinical Nuclear Medicine (2022)

We present the case of a left-sided recurrent juvenile nasopharyngeal angiofibroma (JNA) in a 16-year-old boy who underwent endoscopic excision 2 years back. The preoperative contrast-enhanced MRI and histopathology were in favor of JNA. The follow-up 68Ga-prostate-specific membrane antigen (PSMA) PET/CT scan at 3-month interval revealed complete clearance of disease. Currently, the patient presented with recurrent bleeding and nasal endoscopic examination, and contrast-enhanced MRI revealed a presence of a recurrent tumor. The tumor did not show any uptake on 68Ga-PSMA PET/CT, and postoperative histopathology evaluation confirmed the presence of JNA. Although regarded as a criterion-standard imaging modality for assessment of recurrent or residual JNA, 68Ga-PSMA PET/CT is never 100% specific.
Microwave ablation versus laparoscopic resection as first‐line therapy for solitary 3–5‐cm HCC
Authors: Zhen Wang, Miao Liu, De‐zhi Zhang, Song‐song Wu, Zhi‐xian Hong, Guang‐bin He, Hong Yang, Bang‐de Xiang, Xiao Li, Tian‐an Jiang, Kai Li, Zhe Tang, Fei Huang, Man Lu, Ji‐an Chen, Yu‐cheng Lin, Xiao Lu, Yu‐quan Wu, Xiao‐wu Zhang, Ye‐fan Zhang, Chao Cheng, Huo‐lin Ye, Lan‐tian Wang, Hua‐ge Zhong, Jian‐hong Zhong, Lu Wang, Miao Chen, Fang‐fang Liang, Yi Chen, Yan‐song Xu, Xiao‐ling Yu, Zhi‐gang Cheng, Fang‐yi Liu, Zhi‐yu Han, Wei‐zhong Tang, Jie Yu, Ping Liang
Journal: Hepatology (2022)

Abstract Background and Aims The study objective was to compare the effectiveness of microwave ablation (MWA) and laparoscopic liver resection (LLR) on solitary 3–5‐cm HCC over time. Approach and Results From 2008 to 2019, 1289 patients from 12 hospitals were enrolled in this retrospective study. Diagnosis of all lesions were based on histopathology. Propensity score matching was used to balance all baseline variables between the two groups in 2008–2019 ( n = 335 in each group) and 2014–2019 ( n = 257 in each group) cohorts, respectively. For cohort 2008–2019, during a median follow‐up of 35.8 months, there were no differences in overall survival (OS) between MWA and LLR (HR: 0.88, 95% CI 0.65–1.19, p = 0.420), and MWA was inferior to LLR regarding disease‐free survival (DFS) (HR 1.36, 95% CI 1.05–1.75, p = 0.017). For cohort 2014–2019, there was comparable OS (HR 0.85, 95% CI 0.56–1.30, p = 0.460) and approached statistical significance for DFS (HR 1.33, 95% CI 0.98–1.82, p = 0.071) between MWA and LLR. Subgroup analyses showed comparable OS in 3.1–4.0‐cm HCCs (HR 0.88, 95% CI 0.53–1.47, p = 0.630) and 4.1–5.0‐cm HCCs (HR 0.77, 95% CI 0.37–1.60, p = 0.483) between two modalities. For both cohorts, MWA shared comparable major complications (both p &gt; 0.05), shorter hospitalization, and lower cost to LLR (all p &lt; 0.001). Conclusions MWA might be a first‐line alternative to LLR for solitary 3–5‐cm HCC in selected patients with technical advances, especially for patients unsuitable for LLR.